FDA approves Revolution Medicines' first targeted drug for advanced pancreatic cancer
The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial
We haven't written up this one. Quartz has the full story — the link below goes straight to it.